Jubilant Pharmova:
₹2,123 Cr Revenue. 9.5% ROCE.
FDA Shutdown, API Spin-Off, Tax Demands. Welcome To Hell.
A diversified pharma conglomerate that decided 2025 was a good year to stress-test literally everything. Montreal facility gets an FDA OAI. API business gets spun off. Income tax and GST demons appear. And yet, somehow, the stock only fell 23% in six months. Bargain shopping, or burning money?
The Company That’s Actually Five Companies Pretending to Be One
- 52-Week High / Low₹1,250 / ₹784
- Q3 Revenue (3 months)₹2,123 Cr
- Q3 PAT (Normalised)₹86 Cr
- Q3 EPS (Normalised)₹5.4
- Annualised EPS (Q3×4)₹21.6
- Book Value₹414
- Price to Book2.0x
- Dividend Yield0.60%
- Debt / Equity0.44x
- 6M Return-26.2%
Six Businesses Masquerading as One Stock
Jubilant Pharmova Ltd exists in a state of perpetual identity crisis. It’s an ambitious diversification strategy executed with the precision of a drunk cricket batsman swinging at every ball. The company operates across six major business segments that have about as much synergy as a dentist and a cement factory.
On one side, there’s radiopharmaceuticals — growing 20%+ annually, premium margins, genuine innovation. The 46-pharmacy network in the US is a moat. Ruby-Fill cardiac imaging is a genuine competitive advantage. That’s the crown jewel.
On the other side, generics — the pharmaceutical equivalent of selling salt. Low margins, price wars, government reimbursement nonsense. The company closed its US facility (Salisbury) in 2024 and is now outsourcing. Because in-house generics manufacturing apparently makes no sense when your capex can go to radiopharmaceuticals instead.
Then there’s the API (active pharmaceutical ingredients) business — which just got spun off into a wholly-owned subsidiary called Jubilant Biosys in September 2025. Brilliant move? Or desperate deleveraging? The jury is out. The company transferred the API business on a slump sale basis and issued OCRPS (Optionally Convertible Redeemable Non-Cumulative Preference Shares) worth ₹515.59 crore at ₹100 face value. That’s VC financing with extra steps.
Meanwhile, the Montreal CDMO facility — one of the crown jewels for sterile injectable manufacturing — got an FDA OAI (Observation) in October 2025. Production shut. Remediation began. Production resumed by Q4. But investors were watching their ₹1,250 stock become ₹784. Sometimes watching a company navigate regulatory purgatory is better than actual earnings growth.
The Conglomerate That Can’t Decide What It Wants to Be
Jubilant Pharmova is fundamentally six companies that happen to share a ticker symbol and investor misery.
Radiopharma (45% of 9M FY26 revenue, ₹2,700 Cr annualised): The hero story. Radiopharmaceuticals are specialty chemicals used in medical imaging and cancer treatment. Think of them as drug molecules that glow so doctors can see where the disease is (diagnostic) or deliver radiation therapy directly to tumours (therapeutic). The #3 radiopharmaceutical manufacturer in the US. Ruby-Fill for cardiac imaging is the crown jewel — 25% market share in a market growing 20%+ annually. Real defensibility.
CDMO Sterile Injectables (20% of revenue): Contract manufacturing for other pharma companies. High capex. Long customer relationships (averaging 5+ years). The Spokane facility is churning out business. The Montreal facility just got an FDA timeout. Line 3 is generating revenue from tech transfer programs. Management plans to double capacity by FY30 with a ₹1,500+ Cr capex.
Allergy Immunotherapy (9% of revenue): The HollisterStier brand. Sole supplier of venom immunotherapy in the US. Allergy immunotherapy is essentially controlled exposure therapy — you give patients tiny amounts of what they’re allergic to, they build tolerance. The business has grandfathered regulatory approvals. That moat is real. But growth is low-single-digit. Sexy? No. Profitable? Yes, at 25–40% EBITDA margins.
CRDMO — Drug Discovery (15% of revenue): Contract research and development. Two world-class R&D centres in India (Bengaluru, Greater Noida). Partnerships with large pharma. 8 of top 20 pharma companies are customers. 85+ integrated drug discovery programs delivered. This is the long-term growth engine. But it’s dependent on Big Pharma spending on outsourced R&D. And that’s cyclical.
Generics (9% of revenue): Solid dosage formulations for the US, India, and select non-US markets. Company is unprofitable here (negative EBITDA in FY25). They’re trying to build branded business in India (weight management, diabetes). Roorkee facility is FDA-approved but not scale. Outsourcing to CMOs now. This segment feels like management’s sunk cost fallacy on steroids.
Novel Oncology Drugs: Two lead programs in clinical trials. JBI-802 for blood cancer and lung cancer. JBI-778 for lung cancer and brain tumours. TAM estimated at ₹25,000 Cr+. Expected data readouts in CY26. Company is exploring licensing or external fundraising post data readout. This is venture capital inside a public company. Exciting on a 2030 horizon. Dead money for next 3 years.
The Numbers (Spoiler: It’s Complicated)
Result type: Quarterly Results | Q3 FY26 Reported PAT: ₹56 Cr | Normalised PAT: ₹86 Cr | Annualised Normalised EPS (Q3×4): ₹21.6 | TTM EPS: ₹27.16
Source table
| Metric (₹ Cr) | Q3 FY25 Dec 2024 |
Q3 FY26 Dec 2025 |
Q2 FY26 Sep 2025 |
YoY % | QoQ % |
|---|---|---|---|---|---|
| Revenue | 1,822 | 2,123 | 1,966 | +16.5% | +7.9% |
| Operating Profit (EBITDA) | 296 | 310 | 351 | +4.7% | -11.7% |
| EBITDA Margin % | 16.2% | 14.5% | 17.8% | -170 bps | -330 bps |
| Normalised PAT | 104 | 86 | 124 | -17.3% | -30.6% |
| Normalised EPS (₹) | 6.56 | 5.4 | 7.84 | -17.7% | -31.1% |
What’s a Burning Pharmaceutical Conglomerate Actually Worth?
Method 1: P/E Based
TTM EPS = ₹27.16. Current P/E = 30.4x (way above sector 27.7x). A normalized conglomerate discount to sector would be 0.9x–1.0x. Fair P/E band: 25x–28x.
Range: ₹679 – ₹760
Method 2: EV/EBITDA Based
TTM EBITDA = ₹1,751 Cr (annualised from 9M FY26 figure). Current EV = ₹15,424 Cr (market cap + net debt). EV/EBITDA = 8.8x. Specialty pharma (radiopharm + CDMO) trades at 11x–14x. Generics trades at 8x–10x. Blended fair range: 10x–12x.
EV range (10x–12x): ₹17,510 Cr – ₹21,012 Cr → Net debt ₹2,883 Cr → Equity value per share:
Range: ₹699 – ₹778
Method 3: DCF Based
Base FCF (9M FY26 annualised): ~₹1,100 Cr. Realistic growth: 8–10% for 5 years (conservative given FDA issues). Terminal growth: 2.5%. WACC: 9.5%.
→ Terminal Value (2.5% growth / 7% cap rate): ~₹19,000 Cr
→ Total EV: ~₹24,200 Cr → Less: Net Debt ₹2,883 Cr → Equity Value ₹21,317 Cr
Range: ₹730 – ₹850
Oh, The Chaos In The Pharma Lab
🔴 The Regulatory Nightmare: Montreal CDMO Gets FDA Timeout
In October 2025, the Montreal CDMO facility (critical for US sterile injectable manufacturing) received an OAI (Observation) after FDA inspection. Production shutdown. Investors panicked. Stock dropped ₹100+ per share. Company initiated remediation. By Feb 2026, production resumed. Management’s concall line: “production has been resumed for SPECT products at our CMO in Q4’FY26. Developing alternate CMO’s to mitigate supply-chain risk.” Translation: we’re scrambling to outsource production to third-party CMOs while fixing our own facility. This could take 12–18 months to normalize. Q4 and Q1 FY27 will see revenue impact. Revenue to normalize from Q2 FY27. That’s 5 quarters of uncertainty.
⚠️ API Business Gets Spun Out
- • API business transferred to Jubilant Biosys (wholly-owned subsidiary) on Sept 1, 2025
- • ₹515.59 Cr in preference shares issued at ₹100 FV
- • ₹80 Cr cash infused
- • India Ratings withdrew debt ratings post-transfer (Feb 24, 2026)
- • API was loss-making (FY25: negative EBITDA); deleveraging move
⚠️ Tax & Regulatory Demands Pile Up
- • Income Tax demand: ₹228.75 Cr (Mar 2024)
- • Additional IT demand: ₹22.10 Cr for FY2020 (Dec 2025)
- • GST demands: ₹6.98 Cr + interest + penalty (Jubilant Biosys, Dec 2025)
- • GST adjudication order: ₹6.65 Cr + interest + penalty (Jubilant Biosys)
- • Company claims no material impact; planning appeals
✅ Radiopharmaceuticals Growth Continues
- • Ruby-Fill cardiac imaging: 25% market share, still growing
- • MIBG launch targeting pediatric neuroblastoma (data by Apr–Jun 2026)
- • New PET products pipeline: 9 launches planned, ₹550 Mn+ TAM
- • PET radiopharmacy expansion: 3→9 sites by 2028
- • 9M FY26 radiopharma revenue: ₹2,700 Cr (₹859 Cr manufacturing + ₹1,841 Cr radiopharmacy)
✅ New Capacity Lines Coming Online
- • CDMO SI: Line 3 revenue ramp (commercial production Q2 FY27)
- • CDMO SI: Line 4 in construction (production Q4 FY27)
- • Montreal: New isolator fill-finish line under construction (₹114 Mn capex + ₹35 Mn concessional loan)
- • All targeting 2x capacity by FY30
Is the Capital Structure Sustainable?
Source table
| Item (₹ Cr) | Mar 2024 | Sep 2025 | Dec 2025 | Latest Change |
|---|---|---|---|---|
| Total Assets | 11,338 | 13,521 | 13,521 | +19.3% YoY |
| Net Worth (Equity + Reserves) | 5,434 | 6,576 | 6,576 | +21.0% YoY |
| Borrowings (Debt) | 3,664 | 2,883 | 2,883 | -21.3% (Improvement) |
| Other Liabilities | 2,240 | 4,047 | 4,047 | +80.6% (Worrying) |
| Total Liabilities | 11,338 | 13,521 | 13,521 |
Debt reduced from ₹3,664 Cr to ₹2,883 Cr (-21%). API spin-off freed up ₹515 Cr in OCRPS but didn’t reduce debt. Interest coverage = 6.3x (EBITDA ₹1,751 Cr ÷ Interest ₹275 Cr). That’s healthy. But capex is ₹570 Mn USD (~₹4,800 Cr) over FY23–25. So debt will start rising again.
Other Liabilities jumped from ₹2,240 Cr to ₹4,047 Cr (+81%). This includes trade payables, accrued expenses, and contingent liabilities (the tax demands and GST disallowances). The company is technically sound on liquidity, but regulatory risk is rising.
CWIP (Capital Work In Progress) is at ₹2,344 Cr (Sep 2025). That’s capex in flight. Montreal facility upgrade, Line 3 scale-up, Line 4 construction. When these come online (FY27–28), depreciation will spike, EBITDA margins will compress further.
Can They Actually Generate Cash?
Source table
| Cash Flow (₹ Cr) | FY24 | FY25 | TTM |
|---|---|---|---|
| Operating CF | +971 | +1,072 | +1,100 (annualised) |
| Investing CF | -596 | +512 | -400 (annualised) |
| Financing CF | -432 | -1,453 | -700 (annualised) |
| Free Cash Flow (OCF – CapEx) | +375 | +476 | +700 (annualised) |
Quality Metrics Say the Stock Is Overpriced
Annual Trends — FY24 to TTM
Source table
| Metric (₹ Cr) | FY24 | FY25 | TTM |
|---|---|---|---|
| Revenue | 6,703 | 7,234 | 7,918 |
| EBITDA | 901 | 1,173 | 1,266 |
| EBITDA Margin % | 13.5% | 16.2% | 16.0% |
| PAT (Full Year) | 73 | 836 | 430 |
| EPS (₹) | 4.84 | 52.69 | 27.16 |
FY25 PAT included ₹382 Cr gain from Sofie Biosciences investment sale. Strip that out, normalized FY25 PAT = ~₹450 Cr. So run-rate is ₹420–450 Cr PAT annualised. On ₹13,164 Cr market cap, that’s a 3.2% earnings yield. For context, GSec yields are 6–7%. This stock is yielding 50% of government bonds. For taking 50x+ the volatility.
How Bad Is It Compared to Pharma Peers?
Source table
| Company | TTM Revenue (₹ Cr) | TTM PAT (₹ Cr) | P/E (TTM) | ROCE % | Growth (3Y Sales) |
|---|---|---|---|---|---|
| Jubilant Pharmo | 7,918 | 430 | 30.4x | 9.54% | 5.68% |
| Sun Pharma | 56,809 | 12,137 | 36.1x | 20.21% | 7.56% |
| Divi’s Lab | 10,314 | 2,533 | 65.9x | 20.44% | 25.05% |
| Dr Reddy’s | 34,682 | 5,568 | 19.8x | 22.69% | 6.37% |
| Cipla | 28,351 | 4,755 | 22.5x | 22.72% | 7.23% |
Jubilant is a mega-cap conglomerate (₹13K Cr) trapped in a mid-cap growth story (5.68% sales CAGR) with small-cap returns (9.54% ROCE). The arbitrage is broken.
Who Actually Owns This Burning Building?
- Promoters (Bhartia Family)47.7%
- Non-Institutions (Public)24.6%
- FIIs16.0%
- DIIs11.2%
Pledge: 5.4% (against promoter). Shareholders: 90,133 (declining from 97,935 in Mar 2023). The public is exiting.
Promoter: The Bhartia Family
Shyam S. Bhartia (Chairman), Hari S. Bhartia (Co-Chairman), Priyavrat Bhartia (MD), and Arjun S. Bhartia (Joint MD) sit atop a ₹56,000-person diversified conglomerate spanning pharma, polymers, flavours, beverages, and oil services. The Bhartias own Jubilant directly + another 15+ subsidiary companies. That’s not focus. That’s empire-building. Promoter holding has declined from 50.67% (Mar 2023) to 47.7% (Dec 2025). Slow dilution = either planned capital raise or execution uncertainty.
FIIs Are Quietly Exiting
FII holding dropped from 23.22% (Mar 2023) to 15.96% (Dec 2025). That’s a 7 percentage point exit. DIIs picked up some slack (1.62% → 11.23%), but that’s mostly retail/small cap funds chasing “turn-around” stories. Large global capital is exiting. That’s a red flag.
The Regulatory and Compliance Minefield
✅ Operational Positives
- ✓ Q3 FY26 concall held on schedule (Feb 6, 2026)
- ✓ BRSR (Business Responsibility Report) filed annually
- ✓ ESG disclosure; DJSI participation
- ✓ Multiple board committees (Audit, Remuneration, Nomination)
- ✓ Six manufacturing facilities across US, Canada, India
⚠️ The Governance Landmine
- ⚠ Montreal facility FDA OAI (Oct 2025) — active remediation
- ⚠ Nanjangud facility (API) had OAI in 2023; reverted to VAI by Mar 2024
- ⚠ Income Tax demand: ₹228.75 Cr pending appeal
- ⚠ Multiple GST disallowances totalling ₹15+ Cr across subsidiaries
- ⚠ Interim CFO appointed Sep 2025 (Arun Kumar Sharma effective Oct 1)
- ⚠ MD leadership continuity + two senior scientists left for Jubilant Biosys
The Pharma Landscape: Radiopharm Gold Rush, Generics Apocalypse
The pharmaceutical industry is bifurcating at warp speed. On one end, specialty pharma (oncology, radiopharmaceuticals, rare diseases, CDMO services) is experiencing 15–20% CAGR with 30–50% EBITDA margins. These are defensible, regulated markets with genuine innovation moats. On the other end, generic APIs and solid dosage formulations are compressing at 2–4% CAGR with 8–15% margins. Jubilant is trying to play both sides. That’s strategic incoherence.
🔬 Radiopharmaceuticals: The Real Opportunity
The US radiopharmaceutical market is growing 20%+ annually. PSMA imaging and Lu-177 therapeutics for prostate cancer represent USD 3.8 Bn+ TAM. Advanced therapies are reimbursed at premium rates. Manufacturing is complex (radioactive isotope handling), capital-intensive, and high-barrier. Jubilant’s position as #3 manufacturer with 46 radiopharmacies is genuinely defensible. Ruby-Fill (cardiac PET) with 25% market share in a USD 180 Mn market growing 12%+ is real. This is the only part of Jubilant that justifies a premium valuation. Problem: It’s only 45% of revenue.
💊 Generics: Graveyard Economics
US generic drug market is growing 1–2% annually. Pricing pressure from hospital group purchasing organizations (GPOs) and CVS/Walgreens formulary power is relentless. India-to-US generics exporters are competing on cost at the margin. Jubilant closed its Salisbury facility in 2024 (1.5 Bn dose capacity). Now outsourcing to CMOs. Why? Because in-house manufacturing doesn’t pencil anymore. Roorkee facility exports Risperidone to the US. That’s it. Generics is a cash-burn machine. Yet management still targets ₹1,550 Cr revenue and 15–17% EBITDA by FY30. That requires relaunch of 6–8 dormant ANDAs + branded India business. Possible? Maybe. Probable? No.
🧪 CDMO Services: The Competitive Hammer
Global CDMO market is consolidating. Catalent got acquired by Novo Holding. Lonza is expanding capacity globally. Capacity shortage in sterile injectables is real (demand-supply gap of 700 Mn vials by 2027). But that doesn’t mean all CDMO players prosper. Customer concentration risk is high. Jubilant’s top 5 customers represent significant revenue. Switching costs are high (18–24 months for tech transfer). But pricing power is zero. Margins compress over time as customers source alternate suppliers. Montreal facility FDA issues = customers diversifying. That’s death by a thousand cuts.
🎲 Novel Oncology Drugs: Venture Capital Inside a Public Listing
JBI-802 for blood cancer and JBI-778 for lung cancer are early-stage programs. Phase 1 data is encouraging (patient responses, tumor reduction). But Phase 2–3 is where 90% of programs fail. TAM estimates (USD 7 Bn+) are optimistic. Timelines: data readouts by CY26, potential licensing/out-licensing by CY27–28. If successful, could be ₹500 Cr+ revenue by 2030. If not, ₹0. That’s a venture capital bet, not a pharma business. Carrying this as 0% revenue today makes sense. But it’s burning cash. FY25 had -₹12 Cr EBITDA. That could scale to -₹50 Cr/year if programs progress to Phase 2. Good R&D should lose money. But public company shareholders typically don’t love funding exploratory science without optionality to exit.
Macro tailwinds for Jubilant’s winning segments (Radiopharm + CDMO SI): US drug development pipeline is robust (FDA approvals ~55–60/year). Hospital capex for advanced oncology is increasing. PET imaging adoption is accelerating (especially in cardio, neuro, oncology). Biosecure Act benefits Indian CRDMO. These are real.
Macro headwinds for losing segments (Generics + API): US generic pricing is down 3–5%/year. India API market is facing margin compression from China competition. Regulatory risk (FDA observations, GST disallowances, IT demands) is rising. These are also real.
The Phoenix or the Pile of Ashes?
Jubilant Pharmova is a conglomerate in the middle of an active restructuring. Radiopharmaceuticals are genuinely exceptional (20%+ growth, 40%+ margins, defensible moats). CDMO services are strategic but commoditizing. Generics are dying. Novel drugs are science projects. The Montreal facility got an FDA timeout. The API business got spun off. Tax authorities are circling. The stock fell 34% from 52-week high. At ₹828/share, it’s trading at 30.4x TTM earnings with 9.54% ROCE. That’s expensive for a company in crisis mode.
Q3 FY26 Execution: Revenue grew 16.5% YoY to ₹2,123 Cr quarterly (₹7,918 Cr annualised). But EBITDA grew only 4.7%. And normalised PAT fell 17.3%. That’s margin compression despite top-line growth. Radiopharm was strong. CDMO SI got hit by Montreal. CRDMO was steady. Generics finally showed signs of life. Overall: execution is mixed.
The FDA Situation: Montreal facility OAI is NOT a death sentence. Similar facilities (Insulet, other CDMO players) have weathered FDA observations and come out stronger. But this one hit unexpectedly in Q3 FY26, causing production shutdown, revenue impact expected in Q4 FY26 and Q1 FY27. Remediation is underway. Production resumed by Q4. But customer relationships are damaged. Customers are diversifying to alternate suppliers. That’s permanent competitive loss. Expected recovery: 12–18 months to full capacity utilization.
The API Spin-Off: Jubilant Biosys is now a separate financial entity (99.99% owned). API business had ₹1,751 Cr revenue in 9M FY26, but negative EBITDA margins (-12 Cr EBITDA). Moving loss-making business out of consolidated P&L is deleveraging, not restructuring. The ₹515.59 Cr OCRPS issued is now a contingent liability on the balance sheet. If Jubilant Biosys doesn’t perform, those preference shares get redeemed, and Jubilant Pharmova absorbs the loss. This is financial engineering, not operational improvement.
Vision 2030 Reality Check: Management targets ₹13,500 Cr revenue, 23–25% EBITDA margin, zero net debt, high-teens ROCE by FY30. For that to happen: (1) Radiopharm revenue must grow from ₹2,700 Cr to ₹5,000+ Cr (9% CAGR for 4 years). (2) CDMO SI must double to ₹2,500+ Cr. (3) Generics must turn profitable (+15% EBITDA margin). (4) CRDMO must triple to ₹2,000+ Cr. (5) Novel drugs must launch and generate ₹500+ Cr revenue. That’s a perfect execution scenario. If 1–2 bets fail, Vision 2030 falls apart. ROCE stays at 12–15%, P/E re-rates to 20x (on consolidated multiple compression), and stock re-rates to ₹550–650.
Historical Context: Stock CAGR over 10 years: 9%. Over 5 years: 1%. Over 3 years: 40% (from the lows). Over 1 year: -4.3%. That’s a stock that’s been dead for 5 years, rallied hard from lows, then crashed again on FDA concerns. Classic momentum-to-value trap. FIIs have exited. DIIs have entered. Retail is averaging down or exiting.
✓ Strengths
- Radiopharm market leadership (#3 US manufacturer, 45% revenue)
- Ruby-Fill 25% market share in cardiac PET (₹180 Mn market, 12%+ CAGR)
- 46 radiopharmacies with 20% US market share, on-time delivery 99%+
- CDMO SI: Top 5 pharma customers, 5+ years avg relationships
- Allergy Immunotherapy: Sole venom supplier in US (100-year brand)
- CRDMO: 8 of top 20 pharma as customers; 85+ drug programs delivered
✗ Weaknesses
- Montreal facility FDA OAI; production shutdown (active remediation)
- ROCE only 9.54% vs sector 20%+ (capital inefficiency)
- Generics unprofitable; facility closed; outsourcing to CMOs
- API business in loss-making subsidiary (₹515 Cr OCRPS liability)
- Conglomerate discount: six business units, no synergy visible
- Multiple tax/regulatory demands pending (₹250+ Cr contingent)
→ Opportunities
- Radiopharm market growing 20%+ annually (USD 20 Bn by 2027)
- MIBG pediatric neuroblastoma launch (data CY26, ₹100+ Mn peak sales potential)
- 9 new PET/SPECT products planned (₹550 Mn TAM)
- 6 new PET radiopharmacies (USD 50 Mn investment, 20% ROCE target)
- CDMO SI capacity expansion (Line 3, Line 4, Montreal isolation chamber)
- Novel drugs: JBI-802 and JBI-778 in Phase 2; potential ₹25,000+ Cr TAM
⚡ Threats
- Montreal facility remediation takes 12–18 months; customer losses permanent
- Novel drug programs Phase 2 failures (90% attrition typical)
- Radiopharm competition increasing (Novartis, AstraZeneca, BMS acquiring assets)
- CDMO margin compression from customer concentration and switching
- Generic drug pricing down 3–5%/year; competitive intensity rising
- Regulatory risk from FDA, Income Tax, GST authorities
Jubilant Pharmova is a company with genuine strengths (Radiopharm) drowning in conglomerate noise (generics, API, novelty).
The stock at ₹828 prices in near-perfect execution of Vision 2030. Montreal remediation completes without customer loss. Novel drugs deliver blockbuster data. Radiopharm grows 20%+ for 4 straight years. Generics becomes profitable. That’s asking for five wins simultaneously. History says you get 2–3. If Montreal takes 18 months to recover, novel drug Phase 2 trial shows safety concerns, and Radiopharm growth slows to 12%, ROCE stays at 12–15%, P/E re-rates to 20–22x, and the stock falls to ₹550–650. Conversely, if Radiopharm keeps growing 20%, MIBG launches on schedule, and CDMO SI lines ramp as planned, the stock could justify 28–32x P/E by FY28–29, pushing the price to ₹900–1,000. It’s a 50–50 bet between ₹550 and ₹1,000. That’s not asymmetric edge. That’s a casino.